
EC grants marketing authorisation to rare disease drug
The European Commission (EC) has granted marketing authorisation for Kygevvi (doxecitine and doxribtimine) for the treatment of thymidine kinase 2 deficiency (TK2d). The approval, making Kygevvi the first and only treatment for TK2d, can now be used to treat paediatric and adult patients with the condition with… Read More
